CURRICULUM VITAE - ISAAC P. WITZ, Ph.D.

Date and Place of Birth: November 7, 1934, Vienna, Austria

Academic Education:

1959 - M.Sc.	Hebrew University, Jerusalem. Microbiology, Biochemistry, Parasitology
1965 - Ph.D.	Hebrew University, Jerusalem
	Post-doctoral Training:
1965 - 1968	Cancer Research Scientist, Roswell Park Memorial Institute (with Dr. David Pressman), Buffalo, New York. Tumor Immunology

Ranks in Academic or Research Institutions:

1968 - 1969	Lecturer of Immunology, Tel Aviv University
1969 - 1972	Senior Lecturer of Immunology, Tel Aviv University
1972 - 1975	Associate Professor of Immunology, Tel Aviv University
Aug 73-Feb 74	Visiting Professor, Dept. of Medicine, School of Medicine, University of California, San Francisco
Feb 74-Jan 75	Visiting Professor (Eleanor Roosevelt Fellow), Dept. of Tumor Biology, Karolinska Institute, Stockholm, Sweden
1975 -	Professor of Immunology, Tel Aviv University
1978 - 1979	Consultant and Visiting Scientist, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
1989 - 1990	Visiting Professor, Center for Molecular Medicine and Immunology, Newark, NJ, USA.
Feb-Oct 1991	Visiting Scientist, Lab. of Tumor Cancer Biology, Div. of Cancer Treatment, NCI, NIH, Bethesda, Maryland, USA
Mar 98-Dec 99	Visiting Professor of Immunology, John Wayne Cancer Institute, Santa Monica, CA, USA.
Mar 00-Aug 00	Visiting Professor, Institute for Cancer Research, University of Vienna, Austria.
June 01-Sept 01	Visiting Professor, Institute for Cancer Research, University of Vienna, Austria.
June 02-Sept 02	Visiting Professor, Institute for Cancer Research, University of Vienna, Austria.
June 04-Sept 04	Visiting Professor, MD Anderson Cancer Center, Houston, TX, USA
Nov 04-Feb 05	Visiting Professor, MD Anderson Cancer Center, Houston, TX, USA
July 05-Sept 05	Visiting Professor, Institute for Cancer Research, University of Vienna, Austria.

Professional Occupations:

1969 - 1972	Chairman, Department of Microbiology, Tel Aviv University
1979 - 1984	Head, Tel Aviv University Cancer Biology Research Center
1979 - 1984	Dean, George S. Wise Faculty of Life Sciences, Tel Aviv University
1979 - 1987	Member of the Managing Council, Board of Directors, Tel Aviv Univ.
1979 - 1989	Member of Board of Governors, Tel Aviv University
1981 - 1986	Council Member of the European Association of Cancer Research
1982 - 1989	Director, The Moise and Frida Eskenasy Institute for Cancer Research, Tel Aviv University
1982 - 1989	Member of Editorial Board - Leukemia Reviews

1984 - 1987	Vice President for Research and Development, Tel Aviv University
1984 - 1987	Chairman - Board of Directors, Ramot, Tel Aviv University Authority for Applied Research and Industrial Development
1984 - 1987	Member of the Board of Directors, The Belfer Center for Energy Research Tel Aviv.
1984 - 1992	Member of Executive Council of Ramot, Tel Aviv University Authority for Applied Research and Industrial Development
1986 - 1988	Chairman, The Scientific Reviews Committee, The Landau Prize, Mifal Hapais, Israel
1986 - 1989	President, Israel Immunological Society
1986 - 1989	Council Member of the International Union of Immunological Societies (IUIS)
1991 - 1993	Founding Chairman, Department of Cell Research and Immunology, Tel Aviv Univ.
1994 - 1997	Committee Chairman, French-Israeli Scientific Cooperation in Immunology
1994 - 1997	Member, Honorary Degrees Committee, Tel Aviv University
1995 - 1999	Member, Research Council, Tel Aviv University
1996 - 1999	Member, Committee for Nominations and Promotions, Tel Aviv University
1997 - 2000	Member, Board of Governors, Tel Aviv University
1998 -2001	Head, The Cancer Biology Research Center, Tel Aviv University
1992 -2003	Head, The Ela Kodesz Institute for Research on Cancer Development and Prevention, Tel Aviv University
1981 -	Member of Executive Council and Board of Governors of the Israel Cancer Association
1982 -	Academic Organizer - The Annual Otto Herz Memorial Lectureship in Cancer Research - TAU.
1995 -	Founding Member, Middle Eastern Cancer Society
1995 -	Member, Advisory Committee - Association of Biological Societies of Israel
1996 -	Founding Member and Chairman of Steering Committee, International Cancer Microenvironment Forum
1998 -	Member, Scientific Committee of the German-Israeli Cooperation (Deutsches Krebsforschungszentrum - Ministry of Science) in Cancer Research
2002 -	Consultant, German-Israeli Foundation for Scientific Research & Development
2002-	Member, National Human Experimentation Ethics Committee
2003-	Special Consultant for “Human Immunology” – Dana Foundation, New York, NY, USA
2003-	Scientific Adviser - Dan David Prize, Tel Aviv University
2003-	President, International Cancer Microenvironment Society
2005-	Editorial Board - Clinical & Experimental Metastasis

Membership in Scientific Societies: Israel Immunological Society, American Association for Cancer Research, The Transplantation Society, The American Association of Immunologists, European Association for Cancer Research, The International Cytokine Society, The International Society for Interferon and Cytokine Research, The International Metastasis Research Society, The International Cancer microenvironment Society (Founding president).

Awards and Fellowships:

1960	Gurevitch Award, Hebrew University, Jerusalem, Israel

1961 Anne Frank Fellowship to enable research in Villejuif, France
1974 Eleanor Roosevelt International Cancer Fellowship
1980 Incumbent: The David Furman Chair of Cancer Immunobiology Tel Aviv University
1990 Fogarty Scholar in Residence, NIH, Bethesda, Md., USA
1990 Elected Member of the World Academy of Art and Science
2003 The Jacqueline Seroussi Award for Cancer Research

Isaac P. Witz, Ph.D.

Publications from 2001

152. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, and Ben-Baruch A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol. 167: 4747-4757, 2001.
153. Witz, I.P. Presence and functions of immune components in the tumor microenvironment. Progress in Basic and Clinical Immunology. Adv Exp Med Biol. 495: 317-324, 2001.
154. Eshel, R., Besser, M., Zanin, A., Sagi-Assif, O., and Witz, I.P. The FX enzyme is a functional component of lymphocyte activation. Cell. Immunol. 213: 141-148, 2001.
155. Eshel, R., Zanin, A., Kapon, D., Sagi-Assif, O., Brakenhoff, R., van Dongen, G. and Witz, I.P. The human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head and neck squamous carcinoma cells. Int. J Cancer 98: 803-810, 2002.
156. Neumark, E., Cohn, M.A., Lukanidin, E., Witz, I.P. and Ben-Baruch, A. Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunol. Letters 82: 111-121, 2002.
157. Witz, I.P. The tumour microenvironment - Introduction. Semin Cancer Biol. 12: 87-88, 2002.
158. Eshel, R., Neumark, E., Sagi-Assif, O., and Witz, I.P. Receptors involved in microenvironment-driven molecular evolution of cancer cells. Semin. Cancer Biol. 12: 139-47, 2002.
159. Kahana, O., Micksche, M., Witz, I.P. and Yron, I. The focal adhesion kinase ($P125^{FAK}$) is constitutively active in human malignant melanoma. Oncogene 21: 3969-3977, 2002.
160. Izraeli, S., Witz, I. and Micksche, M. Cancer research--from bench to bedside. Isr. Med. Assoc. J. 4: 746-748, 2002.
161. Levy-Nissenbaum, O., Sagi-Assif, O., Hantisteanu, S., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. PYST2, a MAPK dual specificity phosphatase is regulated by microenvironmental factors. Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 11-17, 2002.
162. Kahana, O., Micksche, M., Witz, I.P. and Yron, I. The possible role of focal adhesion kinase ($P125^{FAK}$) in the malignancy of human melanoma. Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 89-94, 2002.
163. Hantisteanu, S., Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. Adherence up regulates expression of PYST2-L in myeloid leukemia cells. Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 95-100, 2002.

164. Neumark, E., Witz, I.P. and Ben-Baruch, A. Mammary adenocarcinoma progression: potential role of inter-relationships between MCP-1, GM-CSF and TNF alpha. Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 109-114, 2002.
165. Neumark, E., Sagi-Assif, O., Shalmon, B., Ben-Baruch, A. and Witz, I.P. The progression of mouse mammary tumors: a MCP-1 - TNFα cross-regulatory pathway and a clonal expression of pro-malignancy and anti-malignancy factors. Int. J. Cancer, 106: 879-86, 2003.
166. Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. Over expression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Letters, 199: 185-92, 2003.
167. Levy-Nissenbaum, O., Sagi-Assif, O., Kapon, D., Hantisteanu, S., Burg, T., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. The dual-specificity phosphatase PYST2 is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene, 22: 7649-7660, 2003.
168. Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. cDNA microarray analysis reveals an over expression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Meth. Enzymology, 366: 103-113, 2003.
169. Levy-Nissenbaum, O., Sagi-Assif, O. and Witz , I.P. Characterization of the dual-specificity phosphatase PYST2 and its transcripts. Genes, Chromosomes and Cancer, 39: 37-47, 2004.
170. Nevo, I., Sagi-Assif, O., Geminder, H., Goldberg-Bittman, L., Ben-Menachem, S., Shalmon, B., Goldberg, I., Ben-Baruch A. and Witz, I.P. The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunol. Letters, 92:163-169, 2004.
171. Levy-Nissenbaum, O., Barak, E., Burg, T., Sagi-Assif, O., Kloog Y. and Witz I. P. Does the dual-specificity MAPK Phosphatase Pyst2-L lead a monogamous relationship with the Erk2 protein? Immunol. Letters, 92:149-156, 2004.
172. Goldberg-Bittman, L., Neumark, E., Sagi-Assif, O., Azenshtein, A., Meshel, T., Witz, I.P. and Ben-Baruch, A. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Letters, 92:171-178, 2004.
173. Zipin, A., Israeli-Amit, M., Meshel, T., Sagi-Assif, O., Yron, I., Lifshitz, V., Bacharach, E., Smorodinsky, N.I., Many, A., Czernilofsky, P.A., MortonD.L. and Witz, I.P. Tumor-microenvironment interactions. The fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res. 64: 6571-6578, 2004.
174. Goldberg-Bittman L, Sagi-Assif O, Meshel T, Nevo I, Levy-Nissenbaum O, Yron I, Witz IP, Ben-Baruch A. Cellular characteristics of neuroblastoma cells: regulation by the ELR(-)-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine, 29: 105-117, 2005.
175. Witz IP. The involvement of selectins and their ligands in tumor-progression. Immunol Lett. 104: 89-93, 2006.
176. Levy-Nissenbaum O, Ben-Menachem S, Sagi-Assif O, Witz IP. The Pyst2-L phosphatase is involved in cell-crowding. Immunol Lett. 104: 138-45, 2006.
177. Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res. 130: 125-40, 2006.
178. Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. 242: 1-10, 2006.
179. Zipin A, Meshel T, Sagi-Assif O, Shalmon B, Witz IP, Ben-Baruch A. CXCL10 promotes invasion-related properties in colorectal carcinoma cells. Cancer Res. 67: 3396-405, 2007.
180. Witz IP. Yin-yang activities and vicious cycles in the tumor microenvironment. Invited Review. Cancer Res. 2007. In preparation.